Cargando…

T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.

Detalles Bibliográficos
Autores principales:	Sureda-Balari, Anna, Terol, M. José, Domingo-Domènech, Eva, Rodriguez, Ana Pilar González, Mohedo, Francisca Hernández, Céspedes, Javier Núñez, De La Cruz Vicente, Fátima, Muñoz, Carmen Martínez, Díaz, M. Elena Amutio, Córdoba, Raul, Izquierdo, Antonia Rodríguez, Domínguez, Samuel Romero, Meijide, Javier Briones, Greil, Richard, Velázquez, Miriam Moreno, Rubio, Araceli, Oteiro, Mariana Bastos, Gómez, Pilar, Avivi, Irit, Casanova, María, Del Campo García, Raquel, Noriega, Victor, Blanco, José Javier Sánchez, Sanz, Ramón. García
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Relapsed/Refractory
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621516/ http://dx.doi.org/10.1097/01.HS9.0000890960.29449.17

Ejemplares similares

P111: Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
por: Kambhampati, Swetha, et al.
Publicado: (2022)

P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
por: Mei, Matthew, et al.
Publicado: (2022)

P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
por: Michalka, Jozef, et al.
Publicado: (2022)

P106: Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience
por: Erenmalm, Axel, et al.
Publicado: (2022)

P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data
por: Driessen, Julia, et al.
Publicado: (2022)

T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
por: Diefenbach, Catherine, et al.
Publicado: (2022)

P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma
por: Moatti, Hannah, et al.
Publicado: (2022)

P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
por: Shah, Harsh, et al.
Publicado: (2022)

P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.
por: Kamel, Serageldin, et al.
Publicado: (2022)

P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022)

P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma.
por: Mangasarova, Ya.K., et al.
Publicado: (2022)

T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
por: Moskowitz, Alison J., et al.
Publicado: (2022)

P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2022)

P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers
por: Viviani, Simonetta, et al.
Publicado: (2022)

P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
por: Rusconi, Chiara, et al.
Publicado: (2022)

P113: Promising results with anti-PD-1 therapy in primary refractory Hodgkin lymphoma: a single-centre report
por: Zerbi, Caterina, et al.
Publicado: (2022)

Severe hypomagnesaemia with tetany following ESHAP protocol
por: Majumdar, Gautam
Publicado: (2002)

ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
por: Choi, Chul Won, et al.
Publicado: (2002)

Efficacy of ESHAP Regimen in Transplant Ineligible Patients With Relapsed/Refractory T-Cell Lymphoma
por: Norasetthada, Lalita, et al.
Publicado: (2018)

GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
por: Ramzi, Mani, et al.
Publicado: (2015)

ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin's Lymphoma: A Single Center Experience
por: Park, Sang Hyoung, et al.
Publicado: (2006)

Correction: GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
por: Ramzi, Mani, et al.
Publicado: (2015)

P1083: BRENTUXIMAB VEDOTIN, ETOPOSIDE, SOLUMEDROL, HIGH DOSE ARA-C & PLATINUM FOLLOWED BY HDT & APBSCT FOR REFRACTORY/RELAPSED HODGKIN LYMPHOMA PATIENTS: LONG-TERM RESULTS OF THE GELTAMO GROUP BRESHAP STUDY
por: Garcia-Sanz, R., et al.
Publicado: (2022)

Brentuximab Vedotin
Publicado: (2012)

Severe hypophosphatemia induced after first cycle of the ESHAP protocol for Hodgkin’s lymphoma: a case report
por: Elazzazy, Shereen, et al.
Publicado: (2013)

ESHAP chemotherapy is efficient in refractory/relapsed primary central nervous system lymphoma: report of four cases
por: Ungur, Rodica, et al.
Publicado: (2015)

Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma
por: Kim, Do Young, et al.
Publicado: (2022)

PB2323: R-ESHAP VS R-ICE AS RESCUE TREATMENT IN DIFFUSE LARGE B-CELL LYMPHOMA. A SINGLE-CENTEREXPERIENCE.
por: Pérez-Pinilla, Belén, et al.
Publicado: (2023)

Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Boonlerd, Pattamaporn, et al.
Publicado: (2023)

Brentuximab vedotin induced uveitis
por: Therssen, Stijn, et al.
Publicado: (2022)

Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)

Brentuximab vedotin: axonal microtubule's Apollyon
por: Mariotto, S, et al.
Publicado: (2015)

Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin’s Lymphoma in Iran
por: Hatam, Nahid, et al.
Publicado: (2015)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

Brentuximab vedotin: clinical updates and practical guidance
por: Yi, Jun Ho, et al.
Publicado: (2017)

Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review
por: Donato, Eva M, et al.
Publicado: (2018)

Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
por: Wu, Hung-Bo, et al.
Publicado: (2013)

Brentuximab vedotin: targeting CD30 as standard in CTCL
por: Prince, H. Miles, et al.
Publicado: (2018)

Desensitization of Brentuximab Vedotin in a Patient with Hodgkin Lymphoma
por: Khalid, Sidra, et al.
Publicado: (2018)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b209nor7n6njih3b5l11maoss0